Unmet
Clinical Need in Acute Mania Management
Acute
mania is a severe condition that requires quick and effective treatment.
However, 30-40% of patients don’t respond well to standard treatments like
lithium, valproate, or antipsychotics. Current treatments have limitations,
including:
-
Delayed response: Antipsychotics often take 1-2 weeks to work.
-
Safety concerns: Side effects like metabolic issues, movement problems, and
high dropout rates.
-
Treatment resistance: Some patients don’t respond to any treatment, leading to
prolonged hospital stays and poor outcomes.
Clozapine,
which is effective for treatment-resistant schizophrenia, is underused for
acute mania due to Limited research on its use as a first-line treatment, safety
concerns like agranulocytosis and myocarditis and guidelines recommending it
only after other treatments fail.
Biological
Plausibility for Clozapine in Acute Mania
Clozapine’s
effectiveness in mania may be due to its unique mechanisms:
-
Dopamine regulation: Balances dopamine activity without causing severe side
effects.
-
Glutamate modulation: May reduce excitotoxicity.
-
Anti-inflammatory effects: Lowers elevated inflammatory markers.
-
Neuroprotection: Supports brain health by reducing oxidative stress and
promoting BDNF.
Early
evidence suggests clozapine may:
-
Work faster than other treatments
-
Be effective in treatment-resistant cases
-
Have better long-term tolerability compared to other medications
like olanzapine
Research
gap
There’s
a notable gap in Indian research on clozapine for mania, with most studies
focusing on schizophrenia and limited data on its efficacy in bipolar mania.
Moreover, no Indian studies have prospectively assessed the feasibility of ANC
monitoring in manic patients, hindering the adoption of clozapine
in this context.
Clozapine’s
effectiveness in treatment-resistant psychiatric conditions is
well-established, yet its use in bipolar manic episodes remains underexplored
in India, with key knowledge gaps in three areas: (1) feasibility of mandatory
blood monitoring in resource-limited settings, (2) safety comparisons with
standard treatments, and (3) optimal dosing for acute symptom management.
This
gap exists because most clozapine research focuses on schizophrenia, Indian
treatment guidelines lack standardized protocols for using clozapine in
affective disorders, and there’s limited data on monitoring compliance in
public healthcare settings.
Clozapine’s
potential benefits for mania observed in international studies may not
translate to Indian populations due to factors like genetic differences in drug
metabolism, unique healthcare challenges, and variations in
treatment approaches.
Potential
Impact of This Study
By
systematically tracking clozapine’s safety, monitoring compliance, and
treatment outcomes in a representative Central Indian population, this study
aims to generate crucial data for future use
If
clozapine proves feasible and safe for acute mania: It could change treatment
approaches, making clozapine an earlier option, might reduce hospital stays,
saving costs
If
the results are negative, it will clarify clozapine’s role and help avoid
unnecessary risks.
4.
AIM:
To
evaluate the feasibility safety of using clozapine as first line for acute
mania and assess its tolerability
5.
OBJECTIVE
1.Primary
–
Feasibility,
safety and tolerability of clozapine
2.
Secondary –
Time
to clinical response, and Time to remission on clozapine in acute mania
6.
METHODOLOGY
Study Setting –Inpatient Department, Department
of Psychiatry, AIIMS Bhopal
Study design – Prospective observational Study
Study Duration – 24 months
Study Population – Patients of acute mania who are
being treated with clozapine in psychiatry ward of AIIMS Bhopal.
Selection Criteria –
Inclusion Criteria –
Patients
Aged > 18 years of any gender with mania, admitted in the Psychiatry ward at
AIIMS, Bhopal with Signed Informed consent from NR/patient to participate in
the study.
Exclusion criteria-
Patients
with ANC <1500, &
Diabetes
mellitus, epilepsy,
diagnosed
heart disease of
Myocarditis/Pericarditis
History,
Cardiomyopathy
Severe
Arrhythmias AV block, Ventricular
tachycardia/fibrillation history),
Unstable
Coronary Artery Disease (Recent MI, angina)
Heart
Failure
Study Outcome – Outcome Measures
1.
Feasibility,
safety and tolerability Outcomes:
Based
on the questionnaire comprising questions with their answers in ‘yes’ and ‘no’.
Binary outcomes simplify regulatory reporting.
Side
effects scales also for safety and tolerability
2.
Exploratory
Clinical Outcomes
Time
to response (YMRS <50% of baseline), time to remission (YMRS <12)
Sampling:
Prospective
sampling
Sample size:
Study
tools.
·
Questionnaires prepared for the patients
relatives/NR and that for the Clinician
- Young Mania Rating Scale
(YMRS)
- 11
items, assessing core manic symptoms
- 48-hour
timeframe
-
Clinician-administered, 15-30 minutes
-
Scoring: 0-8 (4 items), 0-4 (7 items)
- Total
score: 0-60 (higher = more severe mania)
·
Clinical
Global Impression BP-version (CGI-BP) Scale-
- Is brief, taking
<5 minutes to administer
- Applies to both acute
and maintenance phases
- Offers advantages in
capturing the complex course of bipolar disorder by rating mania, depression,
and mixed states separately
- Improves reliability
with specific anchors and a user’s manual.
- BPRS-Brief psychiatric rating
scale
- If
assessing psychotic features in manic episodes
- Time:
20-30 minutes for interview and scoring
- Method:
Semi-structured interview, clinician observations, and input from
relatives/caregivers
-
Reliability: Improved with dual clinician ratings
-
Clinical use: Assessing symptom severity and tracking changes over time,
particularly for treatment outcome evaluation in psychosis and
severe mental illness.
·
UKU
Side Effect Rating Scale- clinician version
- Assesses broad range
of psychotropic drug side effects
- 48 items, rated 0-3/4
(severity)
- 4 subgroups: Psychic,
Neurological, Autonomic, Other
- Includes global
assessments and causal relation ratings
-
Clinician-administered, structured interview
- Useful for:
- Early drug evaluation
- Comprehensive side effect monitoring
- Research and clinical practice
- Improving patient adherence and safety
Validated in diverse
populations, it’s a standard tool for clinician-rated side
effect assessment.
·
EPS
: modified Simpson-Angus Scale (m-SAS),
-
Modified for practicality, focusing on easily observable items
- 6-item
scale (e.g., gait, rigidity, tremor)
- Used to
monitor extrapyramidal side effects (EPS) in patients on antipsychotics
- New
cut-off score: 0.65 (improved specificity and sensitivity)
-
Facilitates EPS monitoring and communication between clinicians.
|